Although the medication would require a prescription, it will likely be for people with moderate symptoms of Covid-19. Dr Carlos Del Rio, the executive associate dean and a global health expert at the Emory School of Medicine, didn’t hide his excitement, as right now, Covid-19 patients can be only sent home to monitor their symptoms. But having a new and effective pill to offer to these patients would be really life-changing.
For the moment, Merck and Ridgeback announced the results of an ongoing Phase 3 study, which are extremely satisfying. As a matter of fact, they reached such a level of satisfaction, that the FDA, alongside an independent monitoring board, recommended ending the trial early so they can rapidly seek authorization.
